RICHELDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.124
EU - Europa 7.407
AS - Asia 6.146
SA - Sud America 947
AF - Africa 119
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 18
Totale 32.783
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.961
GB - Regno Unito 2.733
CN - Cina 2.115
SG - Singapore 1.792
IT - Italia 1.508
HK - Hong Kong 903
SE - Svezia 792
BR - Brasile 765
DE - Germania 565
UA - Ucraina 488
RU - Federazione Russa 333
VN - Vietnam 332
FI - Finlandia 305
TR - Turchia 302
FR - Francia 187
KR - Corea 186
BG - Bulgaria 166
IN - India 130
ID - Indonesia 106
CA - Canada 96
NL - Olanda 79
AR - Argentina 63
MX - Messico 49
ZA - Sudafrica 46
IE - Irlanda 41
EC - Ecuador 33
IQ - Iraq 32
BD - Bangladesh 31
PK - Pakistan 31
BE - Belgio 30
PL - Polonia 30
JP - Giappone 28
AT - Austria 26
IR - Iran 22
UZ - Uzbekistan 21
ES - Italia 20
NG - Nigeria 20
MY - Malesia 19
CO - Colombia 18
AU - Australia 16
PE - Perù 16
PY - Paraguay 16
AL - Albania 14
CH - Svizzera 13
CL - Cile 13
CZ - Repubblica Ceca 13
EU - Europa 13
TW - Taiwan 13
AE - Emirati Arabi Uniti 12
LT - Lituania 11
MA - Marocco 11
TH - Thailandia 11
VE - Venezuela 11
SA - Arabia Saudita 9
AZ - Azerbaigian 8
DZ - Algeria 8
KE - Kenya 8
DK - Danimarca 7
JO - Giordania 7
TN - Tunisia 7
EG - Egitto 6
PT - Portogallo 6
BO - Bolivia 5
IL - Israele 5
LV - Lettonia 5
OM - Oman 5
RO - Romania 5
UY - Uruguay 5
AM - Armenia 4
EE - Estonia 4
GR - Grecia 4
HN - Honduras 4
HR - Croazia 4
KG - Kirghizistan 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
PA - Panama 4
A2 - ???statistics.table.value.countryCode.A2??? 3
ET - Etiopia 3
LB - Libano 3
NP - Nepal 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BZ - Belize 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
MG - Madagascar 2
PG - Papua Nuova Guinea 2
PH - Filippine 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
Totale 32.761
Salva come PNG Salva come JPEG
Città #
Fairfield 2.177
Southend 2.014
Santa Clara 1.601
Woodbridge 1.472
Ashburn 1.389
Houston 1.140
Singapore 1.102
Jacksonville 958
Chandler 921
Hong Kong 893
Seattle 821
Hefei 804
Dearborn 752
Wilmington 724
Ann Arbor 696
Cambridge 690
Nyköping 452
London 402
Beijing 374
Chicago 255
Los Angeles 242
San Diego 192
Modena 191
Princeton 172
New York 171
Sofia 164
Seoul 161
Eugene 158
Helsinki 133
Izmir 124
Buffalo 116
The Dalles 110
Ho Chi Minh City 108
Council Bluffs 106
Salt Lake City 103
Milan 94
Shanghai 88
Moscow 81
Hanoi 80
Jakarta 70
Dallas 66
Rome 64
Naples 60
Des Moines 57
Tampa 56
Columbus 55
São Paulo 55
Palermo 51
Redwood City 49
Bremen 46
Phoenix 42
Frankfurt am Main 40
Dublin 38
Elk Grove Village 36
Boardman 34
Guangzhou 33
Brussels 30
Florence 30
Norwalk 29
San Francisco 28
Bari 26
Dong Ket 26
Montreal 26
Turin 26
Chennai 25
Jersey City 25
Sterling 25
Warsaw 25
Munich 23
Rio de Janeiro 23
Kunming 22
Detroit 20
Kent 20
Lancaster 20
Tashkent 20
Falls Church 19
Mumbai 19
San Mateo 19
Toronto 19
Boston 18
Brooklyn 18
Long Branch 18
Philadelphia 18
Tokyo 18
Leawood 17
Miami 17
Nanjing 16
Orem 16
Belo Horizonte 15
Denver 15
Haiphong 15
Jinan 15
Mexico City 15
Turku 15
Wuhan 15
Changsha 14
Atlanta 13
Bologna 13
Brasília 13
Dulles 13
Totale 23.955
Salva come PNG Salva come JPEG
Nome #
Malattie infiltrative diffuse del polmone 1.054
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 740
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 421
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 385
Non-steroid agents for idiopathic pulmonary fibrosis 385
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 367
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 349
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 340
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 337
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 335
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 329
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 326
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 309
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 309
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 307
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 293
Aortic pulse wave velocity measurement in systemic sclerosis patients. 291
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 290
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 284
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 278
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 276
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 269
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 264
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 260
Rifabutin for treating pulmonary tuberculosis. 259
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 256
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection 255
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 254
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 252
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 251
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 251
Novel drug targets for idiopathic pulmonary fibrosis 250
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 249
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis 248
Pulmonary fibrosis and the many faces of UIP 243
Macrolides in the treatment of asthma and cystic fibrosis 242
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 242
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 240
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 239
Emerging drugs for idiopathic pulmonary fibrosis. 236
Management of Idiopathic Pulmonary Fibrosis 235
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 235
Smoking-related interstitial lung disease 234
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 234
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 233
An update on the diagnosis of tuberculosis infection 230
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 230
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 229
Early diagnosis of subclinical multi drug-resistant tuberculosis 229
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 228
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 228
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 224
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 224
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 224
Sarcoidosis: challenging diagnostic aspects of an old disease. 222
Blood tests for diagnosis of tuberculosis - Reply 216
Management of idiopathic pulmonary fibrosis. 216
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 216
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management 214
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 211
Prevalence and prognosis of unclassifiable interstitial lung disease 209
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 209
The big clinical trials in idiopathic pulmonary fibrosis. 202
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 202
Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy 199
The complex interrelationships between chronic lung and liver disease: a review. 198
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 198
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 198
Immunomodulatory agents for idiopathic pulmonary fibrosis. 196
Tubercolosi 196
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 196
Macrolides for chronic asthma. 195
ANTIBODY REPERTOIRE AGAINST THE A60 ANTIGEN COMPLEX DURING THE COURSE OF PULMONARY TUBERCULOSIS 194
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 194
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 194
Challenges in idiopathic interstitial lung disease 193
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 193
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 192
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 192
Interferon gamma assays for tuberculosis 191
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 188
Interaction of genetic and exposure factors in the prevalence of berylliosis 186
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 186
Genetic testing in diffuse parenchymal lung disease 185
Co-trimoxazole effect on human alveolar macrophages of AIDS patients 184
L'infezione tubercolare nel bambino: il contributo dei nuovi test immunologici 183
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 182
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. 182
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 182
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 181
The role of biomarkers in low respiratory tract infections. 181
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 179
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. 178
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis 178
Tuberculosis diagnostic tests: Sensitivity, specificity, and comparing apples with apples 177
To BAL or not to BAL: is this a problem in diagnosing IPF? 176
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 174
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 174
Idiopathic pulmonary fibrosis: current challenges and future perspectives 173
Mycobacterium tuberculosis induces CCL18 expression in human macrophages 173
Totale 24.820
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.022 0 0 0 0 0 262 292 444 165 417 243 199
2021/20222.903 86 488 275 221 59 87 200 108 293 208 525 353
2022/20232.694 324 274 169 241 317 402 47 292 331 81 116 100
2023/20242.023 62 129 124 173 372 244 245 244 67 47 128 188
2024/20255.889 212 90 84 417 1.236 847 389 367 631 357 585 674
2025/20265.473 676 489 1.084 1.283 1.747 194 0 0 0 0 0 0
Totale 32.982